Business, energy, technology, markets and global industry news from Business News Today

Dupilumab

PharmaDeviceNews Dupilumab
Representative image: A dermatologist examines chronic hand eczema as LEO Pharma’s ESCD 2026 data highlight the condition’s impact on work, school participation and daily life.
Pharma & Biotech

One antibody could target both eczema inflammation and itching. Zai Lab’s first human results are coming

Zai Lab will present initial Phase 1 data for ZL-1503 at ACAAI 2026 on November 13, evaluating safety, pharmacokinetics and inflammatory biomarkers in healthy volunteers. The investigational bispecific antibody targets IL-13 and IL-31 receptor signaling, but clinical efficacy in patients with atopic dermatitis remains unreported.

Read More
Representative image of a child undergoing a dermatology skin examination, illustrating the growing focus on pediatric eczema treatment as Galderma’s nemolizumab phase II data sharpen competition in the biologic landscape for atopic dermatitis.
Pharma & Biotech

Nemolizumab improved itching and sleep for a year in young children. Can Galderma expand its FDA label?

Nemolizumab improved itching and sleep for a year in young children. Can Galderma expand its FDA label?

Read More
Representative image of an atopic dermatitis drug development concept, illustrating how Zai Lab’s ZL-1503 is being positioned to target itch and inflammation pathways in early-stage immunology research.
Pharma & Biotech

Can Zai Lab’s ZL-1503 turn dual-pathway itch control into a real atopic dermatitis advantage?

Zai Lab’s ZL-1503 showed durable preclinical itch and inflammation control. Read what its 2026 clinical path could mean for atopic dermatitis.

Read More
Representative image of a child undergoing a dermatology skin examination, illustrating the growing focus on pediatric eczema treatment as Galderma’s nemolizumab phase II data sharpen competition in the biologic landscape for atopic dermatitis.
Pharma & Biotech

What Galderma’s nemolizumab phase II data mean for the competitive biologic landscape in pediatric eczema

Galderma's nemolizumab phase II data in children aged 2-11 show 52-week itch and lesion relief. Read the analysis.

Read More
Pharma & Biotech

Can Regeneron Pharmaceuticals redefine allergy treatment with Phase 3 allergen-blocking antibodies and Dupilumab expansion

Find out how Regeneron Pharmaceuticals’ AAAAI 2026 data could reshape allergy treatment strategies and regulatory expectations.

Read More